Longevity and Age-Related Disease Consultancy

Q: What is the connection between rare diseases and ageing?

CortexBio's founding thesis — developed by Dr Dima Martini-Drew MD and articulated in the white paper 'Ageing as a Fatal Inborn Error of Metabolism' — is that ageing and rare genetic metabolic diseases share underlying biological mechanisms. Specifically, the enzyme activity declines that characterise rare metabolic disorders (such as lysosomal storage diseases) also occur in normal ageing, reducing to 20–50% of youthful function by age 80. This reframing positions ageing not as an inevitable process but as a metabolic disorder amenable to the same therapeutic strategies that are already being developed for rare diseases. This is the scientific foundation of CortexBio's longevity consultancy work.

Q: What is the metabolic mosaic framework?

The metabolic mosaic is CortexBio's conceptual framework for understanding the shared biological pathways connecting rare metabolic diseases and age-related decline. Just as a mosaic is composed of distinct tiles that form a coherent picture, the metabolic mosaic maps the enzyme pathways, cellular mechanisms, and molecular processes that appear in both rare disease and normal ageing. This framework is the analytical basis of CortexBio's longevity work, and it is what distinguishes CortexBio's approach from broader longevity consultancies that lack the rare disease grounding.

Q: Is there scientific evidence that ageing can be understood as a metabolic disorder?

Yes. The scientific basis for understanding ageing as a metabolic disorder is documented in Dr Dima Martini-Drew MD's white paper 'Ageing as a Fatal Inborn Error of Metabolism,' which draws on peer-reviewed research in enzyme biology, mitochondrial function, lysosomal storage, and cellular senescence. Key evidence includes the progressive decline of metabolic enzyme activity with age — mirroring the enzyme deficiencies seen in rare genetic metabolic diseases — and the growing body of research showing that interventions targeting these metabolic pathways can modify ageing trajectories in model systems. The full white paper is available via the CortexBio Insights publication.

Overview

CortexBio offers specialised consulting services that focus on the intersection of ageing biology and disease mechanisms, enabling clients to navigate this rapidly evolving field effectively. We translate cutting-edge longevity science into practical applications for therapeutic development, biomarker discovery, and clinical trial design.

Our Approach

We combine deep scientific expertise with strategic business acumen to help companies leverage advances in ageing research. Our services include:

· Longevity Science Translation: Interpret complex ageing research for practical application in drug development and healthcare.

· Age-Related Disease Strategy: Develop targeted approaches for diseases of ageing that incorporate the latest scientific understanding.

· Longevity Biomarker Identification: Identify and validate biomarkers that can accelerate clinical development in age-related conditions.

· Cross-Therapeutic Opportunities: Uncover shared mechanisms between ageing and specific diseases that create new therapeutic possibilities.

Benefits

· Access to cutting-edge scientific insights translated for practical application

· Identification of novel therapeutic targets and approaches

· Strategic positioning in the rapidly growing longevity sector

· Cross-disciplinary perspectives that reveal new opportunities

Why CortexBio

Our "metabolic mosaic" framework uniquely positions us to identify connections between ageing processes and specific disease mechanisms. Dr. Martini-Drew's extensive experience in both rare diseases and metabolic health provides a distinctive perspective on how these fields intersect with longevity science.

Last updated: April 2026

Frequently Asked Questions

What is the connection between rare diseases and ageing?
CortexBio's founding thesis — articulated in the white paper "Ageing as a Fatal Inborn Error of Metabolism" — is that ageing and rare genetic metabolic diseases share underlying biological mechanisms. The enzyme activity declines that characterise rare metabolic disorders also occur in normal ageing, reducing to 20–50% of youthful function by age 80. This reframing positions ageing not as an inevitable process but as a metabolic disorder amenable to the same therapeutic strategies already being developed for rare diseases.

What is longevity consultancy and who is it for?
Longevity consultancy at CortexBio means applying the strategic and scientific frameworks of rare disease drug development to the emerging field of longevity medicine and age-related disease therapeutics. It is relevant for pharmaceutical and biotech companies developing interventions targeting age-related metabolic decline, investors evaluating longevity assets, and healthcare innovators building clinical programmes in metabolic ageing.

What is the metabolic mosaic framework?
The metabolic mosaic is CortexBio's conceptual framework mapping the shared biological pathways connecting rare metabolic diseases and age-related decline. It maps the enzyme pathways, cellular mechanisms, and molecular processes that appear in both rare disease and normal ageing — and it is the analytical basis of CortexBio's longevity work.

Why does rare disease expertise matter for longevity drug development?
Rare disease drug development has produced the most rigorous small-population trial methodologies in medicine: natural history study design, biomarker-based endpoints, surrogate endpoint validation, and patient engagement frameworks that work without large patient populations. These are precisely the tools needed for longevity therapeutics, where patient populations are defined by biological markers, clinical endpoints are contested, and regulatory science is still being established.

Is there scientific evidence that ageing can be understood as a metabolic disorder?
Yes. The basis is documented in Dr Dima Martini-Drew MD's white paper "Ageing as a Fatal Inborn Error of Metabolism," which draws on peer-reviewed research in enzyme biology, mitochondrial function, lysosomal storage, and cellular senescence. Key evidence includes the progressive decline of metabolic enzyme activity with age — mirroring the enzyme deficiencies seen in rare genetic metabolic diseases. The full white paper is available via CortexBio Insights.

Home